| Phase 2 Final Results Expected in 1H 2012 RADNOR, Pa., Jan. 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced that it has completed enrollment of 215 patients in its multinational Phase 2 clinical trial designed to evaluate PMX-30063 defensin-mimetic antibiotic in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staphylococc...continued PYMX cd45 heparin Healthcare |
Wednesday, January 4, 2012
PolyMedix Completes Enrollment in Phase 2 Trial With PMX-30063 Defensin-Mimetic Antibiotic
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment